Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 87,507 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 87,507 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $36.81, for a total value of $3,221,132.67. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $147,240. This represents a 95.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Simrat Randhawa also recently made the following trade(s):

• On Friday, November 14th, Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34.

Dianthus Therapeutics Trading Up 15.1%

Shares of DNTH stock traded up $5.35 during trading hours on Friday, hitting $40.85. The company’s stock had a trading volume of 1,574,910 shares, compared to its average volume of 505,087. The business has a fifty day moving average of $35.94 and a 200-day moving average of $25.62. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $41.15. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -11.74 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. On average, equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the stock. Raymond James Financial Inc. increased its position in shares of Dianthus Therapeutics by 686.4% during the third quarter. Raymond James Financial Inc. now owns 11,245 shares of the company’s stock worth $442,000 after acquiring an additional 9,815 shares during the last quarter. Acuta Capital Partners LLC purchased a new position in Dianthus Therapeutics in the third quarter valued at about $984,000. Balyasny Asset Management L.P. acquired a new stake in Dianthus Therapeutics during the 3rd quarter valued at approximately $17,460,000. Longaeva Partners L.P. purchased a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $984,000. Finally, Brooklyn Investment Group acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $262,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. HC Wainwright upped their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday. Raymond James Financial reissued an “outperform” rating and set a $63.00 price objective (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. Stifel Nicolaus upped their price objective on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Finally, Robert W. Baird boosted their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $63.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.